Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 600

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 600
---
2024 and December 31, 2023, Tvardi had $9.4 million and $22.9 million in cash and cash equivalents, respectively, which are primarily maintained in accounts with multiple financial institutions in the United States. Tvardi may maintain cash and cash equivalent balances in excess of Federal Deposit Insurance Corporation limits. Tvardi does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Tvardi’s primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration and low risk profile of Tvardi’s cash equivalents, it believes an immediate 10% change in interest rates would not have a material effect on their fair market value.

Effects of Inflation

Inflation generally affects Tvardi by increasing the cost of labor and research and development contract costs. Tvardi does not believe inflation has had a material effect on its results of operations during the periods presented in its financial statements included elsewhere in this proxy statement/prospectus.

Foreign Currency Exchange Risk

All of Tvardi’s employees and its operations are currently located in the United States, and expenses are generally denominated in U.S. dollars. As such, Tvardi is not exposed to financial risks from exchange rate fluctuations between U.S. dollars and other currencies.

<div align='center'>329</div>

MANAGEMENT FOLLOWING THE MERGER The following table provides information regarding the expected directors and executive officers of the combined company following the closing of the Merger:

| ​                           | ​ |   ​ | ​ | ​                                                     |
| Name                        |   | Age |   | Position                                              |
| Imran Alibhai, Ph.D.        |   |  48 |   | Chief Executive Officer and Director                  |
| Dan Conn, J.D., M.B.A.      |   |  57 |   | Chief Financial Officer                               |
| John Kauh, M.D.             |   |  51 |   | Chief Medical Officer                                 |
| Jeffrey Larson, Ph.D., DABT |   |  63 |   | Senior Vice President, Research & Development         |
| Yixin “Joseph” Chen, Ph.D.  |   |  64 |   | Vice President, Chemistry, Manufacturing and Controls |
| Sujal Shah                  |   |  51 |   | Chairman of the Board                                 |
| Wallace Hall                |